Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ-0,39
KB0,43
PKN120,5121,80,75
Msft1,16
IBM0,73
DCX68,3368,36-0,84
PFE0,50
23.10.2017 5:04:21
Indexy online
AD Index online
select
AD Index online
 

  • 20.10.2017
Eagle Pharm (NASDAQ Cons)
Závěr k 20.10.2017 Změna (%) Změna (USD) Objem obchodů (ks)
52,00 2,91 1,47 297 124
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 23.10.2017
Popis společnosti
Obecné informace
Název společnostiEagle Pharmaceuticals Inc
TickerEGRX
Kmenové akcie:Ordinary Shares
RICEGRX.O
ISINUS2697961082
Poslední známé roční výsledky31.12.2016
Poslední známé čtvrtletní výsledky30.6.2017
Počet zaměstnanců k 31.12.2016 77
Akcie v oběhu k 2.8.2017 15 169 241
Počet akcionářů k 31.12.2016 6
MěnaUSD
Konstituent indexůS&P 600 Small Cap
Kontaktní informace
Ulice50 Tice Blvd Ste 315
MěstoWOODCLIFF LAKE
PSČ07677-7637
ZeměUnited States
Kontatní osobaLisa Wilson
Funkce kontaktní osobyIR Contact Officer
Telefon12 013 265 300
Fax13026365454
Kontatní telefon12 124 522 793

Business Summary: Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company's product portfolio includes products, including Argatroban; Ryanodex; docetaxel injection, non-alcohol formulation; and Bendeka. Its advanced candidates include EP-3101 (bendamustine Resistance Temperature Detectors (RTD)) (EP-3101), EP-4104 (dantrolene sodium for exertional heat stroke (EHS)) (EP-4104), EGL-4104-C-1702 (dantrolene sodium for drug induced hyperthermia), EP-5101 (pemetrexed) (EP-5101) and EGL-5385-C-1701 (fulvestrant). Its product portfolio focuses on oncology, critical care and orphan diseases. Bendamustine is an alkylating agent approved for use in chronic lymphocytic leukemia (CLL), and indolent B-cell non-Hodgkin's lymphoma (NHL), that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.
Financial Summary: BRIEF: For the six months ended 30 June 2017, Eagle Pharmaceuticals Inc revenues increased 80% to $126.9M. Net income increased from $12.2M to $27.4M. Revenues reflect Royalty revenue increase of 81% to $73.9M, License and other revenue increase from $6M to $25M, Product sales increase of 18% to $28M. Basic Earnings per Share excluding Extraordinary Items increased from $0.78 to $1.80.
Odvětvová klasifikace
TRBC2009Biotechnology / Medical Research
TRBC2012Specialty & Advanced Pharmaceuticals
RBSS2004Pharmaceuticals - Generic & Specialty
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSPharmaceutical Preparation Manufacturing
NAICSResearch and Development in the Physical, Engineering, and Life Sciences
SICPharmaceutical Preparations
SICCommercial Physical Research



  • Poslední aktualizace: 23.10.2017
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Independent Chairman of the BoardMichael Graves5428.6.201628.6.2016
Chief Executive Officer, Independent DirectorScott Tarriff572.1.2017
Chief Financial Officer, Principal Financial Officer, Principal Accounting OfficerPete Meyers4715.5.201715.5.2017
Chief Financial OfficerDavid Riggs65
Executive Vice President, Chief Scientific OfficerSteven Krill57
Executive Vice President, Chief Medical OfficerAdrian Hepner55